

NOVOGEN LIMITED



2 July 2015

Mrs Violetta Codreanu

Adviser, Listings Compliance (Sydney)
ASX Compliance Pty Ltd
20 Bridge St, Sydney NSW 2000

By electronic lodgement

Dear Violetta,

Novogen Limited (ASX:NRT) – Corrections in Appendix 3B

I refer to the Appendix 3B released to the market on Tuesday 30 June 2015 (**Appendix**).

On page 2, section 3(b) and (c) of the Appendix, the exercise price of unlisted options expiring 30 June 2020 is incorrect.

On page 2, section 6(c) of the Appendix, the disclosure was amended.

Therefore, I attach a corrected version of the Appendix.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Lionel Mateo". The signature is fluid and cursive, with a long horizontal stroke at the end.

Lionel Mateo

Company Secretary

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Novogen Limited ("Novogen")

ABN

37 063 259 754

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|---|--|
| 1 | +Class of +securities issued or to be issued | Fully paid ordinary share (Shares)
Unlisted options, with various exercise price and expiry date, to purchase ordinary shares (Options) |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | a. 6,378 Shares
b. 77,625,000 Options
c. 6,570,000 Options |

+ See chapter 19 for defined terms.

<p>3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)</p>	<p>a. Fully-paid ordinary voting shares Ranks pari passu with all existing Ordinary Shares</p> <p>b. 1) 51,750,000 options exercisable at \$0.30 and expiring 30/12/2015 2) 25,875,000 options exercisable at \$0.40 and expiring 30/06/2020</p> <p>c. 1) 1,380,000 options exercisable at \$0.30 and expiring 30/12/2015 2) 5,190,000 options exercisable at \$0.40 and expiring 30/06/2020</p>
<p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>a. All the Shares referred to in item 2 will rank pari passu with all existing Ordinary Shares</p> <p>b. All underlying ordinary shares referred to in item 2 will rank pari passu with all existing ordinary shares</p> <p>c. All underlying ordinary shares referred to in item 2 will rank pari passu with all existing ordinary shares</p>
<p>5 Issue price or consideration</p>	<p>a. 1) 5,378 Shares at \$0.30 per share 2) 1,000 Shares at \$0.40 per share</p> <p>b. None</p> <p>c. None</p>
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>a. The Shares referred to in the item 2 are issued in order to provide sufficient funds to develop the Company's drug pipeline and general working capital</p> <p>b. Options issued following the private placement as announced by the Company on 21 April 2015 and approved by shareholders on 24 June 2015.</p> <p>c. Options issued as consideration to the agents who acted as agents and/or advisors for the capital raise.</p>

6a	<p>Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>	yes
6b	The date the security holder resolution under rule 7.1A was passed	12 November 2014
6c	Number of +securities issued without security holder approval under rule 7.1	N/A
6d	Number of +securities issued with security holder approval under rule 7.1A	N/A
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of +securities issued under an exception in rule 7.2	All securities issued are expected to fall within Exception 3 of Listing Rule 7.2. The Shares issued make up the shortfall of the pro rata issue to holders of ordinary securities.
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	<p>Listing Rule 7.1: 6,821,635</p> <p>Listing Rule 7.1A: 8,938,858</p> <p>Total = 15,760,492</p>

+ See chapter 19 for defined terms.

7 **+Issue dates**

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

30 June 2015

8 **Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)**

Number	+Class
423,116,465* * Discrepancy of 1 share fixed, which arose from previous Appendix 3B.	Ordinary Shares

	Number	+Class
9		Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)
	5,614,224	Unlisted options with exercise price of \$0.125 and expiry date of 18/11/2015.
	466,470	Unlisted options with exercise price of \$0.15 and expiry date of 16/12/2019.
	1,199,521	Unlisted options with exercise price of \$0.15 and expiry date of 18/12/2019.
	60,000,000	Unlisted convertible notes, with face values of \$1,500,000
	58,971,151	Unlisted options with exercise price of \$0.30 and expiry date of 4 December 2015
	29,485,999	Unlisted options with exercise price of \$0.40 and expiry date of 4 June 2020
	51,750,000	Unlisted options with exercise price of \$0.30 and expiry date of 30 December 2015
	25,875,000	Unlisted options with exercise price of \$0.40 and expiry date of 30 June 2020
	1,380,000	Unlisted options with exercise price of \$0.30 and expiry date of 30 December 2015
	5,190,000	Unlisted options with exercise price of \$0.40 and expiry date of 30 June 2020

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A
----	--	-----

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
----	---------------------------------------	-----

12	Is the issue renounceable or non-renounceable?	N/A
----	--	-----

13	Ratio in which the +securities will be offered	N/A
----	--	-----

+ See chapter 19 for defined terms.

14	+Class of +securities to which the offer relates	N/A
15	+Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A

+ See chapter 19 for defined terms.

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

+ See chapter 19 for defined terms.

32 How do security holders dispose of their entitlements (except by sale through a broker)?

33 ⁺Issue date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of ⁺securities
(tick one)

(a) ⁺Securities described in Part 1

(b) All other ⁺securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders

36 If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories

1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional ⁺securities

+ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38 Number of +securities for which +quotation is sought

--

39 +Class of +securities for which quotation is sought

--

40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

--

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

--

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)		

+ See chapter 19 for defined terms.

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



.....Date:30/06/2015.....

(Director/Company secretary)

Print name:Lionel Mateo.....

== == == == ==

+ See chapter 19 for defined terms.